Partenaire privilégié de l'industrie cosmétique, pharmaceutique et chimique, StratiCELL, société fondée début 2005, caractérise l'inocuité et l'efficacité dermo-cosmétique de différents actifs et produits au moyen de modèles et de tests in vitro et ce, dans un environnement BPL.
L'activité de StratiCELL est axée sur la production et la commercialisation d'épidermes reconstitués, destinés aux tests in vitro. Par ailleurs, StratiCELL preste de nombreux services qui permettent de caractériser les produits à usage cutané.
Epidermal Differentiation
The stratum corneum from epidermis provides a physical and permeability barrier, which is continuously regenerated by terminally differentiating keratinocytes. It is formed by the subcellular organization of epidermal proteins and lipids into a two-compartment system with a continuous extracellular lipid matrix surrounding the lipid-depleted, protein-enriched corneocytes.
The StratiCELL reconstituted epidermis undergoes a similar epidermal differentiation process, as in human skin.
Cell proliferation, differentiation and death occur sequentially and each process is characterized by the expression of specific proteins.
In Vitro biological endpoints for Epidermal differentiation
- Localization and/or quantification of structural proteins involved in the epidermal differentiation, by immuno-fluorescence or immuno-histology, in StratiCELL reconstituted epidermis (K10, filaggrin, loricrin...)
- Gene expression profiling of key genes involved in epidermal differentiation
|
|
|
Immunofluorescence of Filaggrin/Keratin 10 in sections of StratiCELL® reconstituted human epidermis EPI/001 |
